News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
Study achieves primary endpoint; tenapanor well-tolerated in treated patients Company to hold conference call at 8:30 a.m. ET today
View HTML
Toggle Summary Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
Company on track to report data from T3MPO-1 Phase 3 trial of tenapanor in IBS-C in Q2 2017
View HTML
Toggle Summary Ardelyx To Present at Upcoming Spring Medical Meetings
FREMONT, Calif. , April 18, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that it will present clinical and preclinical data during two poster
View HTML
Toggle Summary Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
FREMONT, Calif. , Feb. 27, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that Mike Raab , chief executive officer of Ardelyx , will present at the
View HTML
Toggle Summary Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
Announced Positive Data From Phase 3 Trial of Tenapanor in Hyperphosphatemia; Company Plans to Initiate Second Phase 3 Trial Mid-Year 2017Phase 3 T3MPO-1 and T3MPO-2 Trials in IBS-C on Track to Readout By Mid-and End-of-Year 2017
View HTML
Toggle Summary Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Tenapanor Represents First Small Molecule, Non-Binder Treatment to Demonstrate Statistically Significant Effect in HyperphosphatemiaTenapanor Exhibits Favorable Tolerability Profile; Company Plans to Initiate Second Phase 3 TrialCompany to Host Conference Call Today at 8:30 a.m. ET
View HTML
Toggle Summary Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
FREMONT, Calif. , Jan. 3, 2017 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial
View HTML
Toggle Summary Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
FREMONT, Calif. , Jan. 3, 2017 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced that Mike Raab , chief executive officer of Ardelyx , will present a company
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress
Enrollment Completed in Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with ESRD on DialysisConference call to be held today at 4:05 p.m. ET
View HTML
Toggle Summary Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016
FREMONT, Calif. , Oct. 31, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that management will host a conference call and audio webcast on Monday, November 7, 2016 , at 4:05 p.m.
View HTML